Study guide
11.1 Section 503A vs. 503B Compounding Facilities (DQSA Architecture)
NABP MPJE Multistate Pharmacy Jurisprudence Examination Exam
Track your progress as you read
Finished sections get a check mark.
1 Chapter 1: Pharmacist Licensure & Reciprocity
1.1 Initial Licensure Requirements & Examinations 1.2 License Renewal, Continuing Education (CE) & Status 1.3 Reciprocity, License Transfer & Multistate Licensure 1.4 Disciplinary Actions, Board Hearings, Sanctions & Reinstatement
2 Chapter 2: Pharmacy Personnel Roles & Supervision Ratios
2.1 Pharmacy Interns: Scope of Practice, Supervision & Preceptor Rules 2.2 Pharmacy Technicians: Registration, Certification & Permitted Duties 2.3 Technician-to-Pharmacist Ratios & Delegated Tasks 2.4 Non-Pharmacist Personnel & Automated Dispensing Technology Roles
3 Chapter 3: Prescriptive Authority & Practitioner Categories
3.1 Physicians, Dentists, Veterinarians & Podiatrists: Prescribing Scope 3.2 Mid-Level Practitioners: APNs, PAs, Optometrists & Independent Authority 3.3 Out-of-State, Foreign & Deceased Practitioner Prescriptions 3.4 Self-Prescribing & Prescribing for Family Members
4 Chapter 4: Patient Counseling & Drug Utilization Review (OBRA '90)
4.1 OBRA '90 Mandates & Prospective Drug Utilization Review (DUR) 4.2 Patient Counseling Requirements, Offer-to-Counsel & Documentation 4.3 Patient Profile Requirements & Retrospective DUR
5 Chapter 5: Advanced Pharmacist Practice & Collaborative Agreements
5.1 Collaborative Practice Agreements (CPAs) & Protocol-Based Care 5.2 Pharmacist Immunization Authority & Vaccine Administration Protocols 5.3 Medication Therapy Management (MTM) & Point-of-Care Testing (POCT) 5.4 Hormonal Contraceptive, Naloxone & Post-Exposure Prophylaxis (PEP/PrEP) Prescribing
6 Chapter 6: Federal Controlled Substances Act (CSA) & Scheduling
6.1 Controlled Substance Schedules (CI through CV) & Classification Criteria 6.2 DEA Registration: Types, Forms (224, 225, 363) & Renewal Cycles 6.3 Scheduled Listed Chemical Products (SLCPs) & Combat Methamphetamine Epidemic Act (CMEA)
7 Chapter 7: Controlled Substance Prescriptions & Legitimate Purpose
7.1 Corresponding Responsibility & Red Flags for Improper Prescribing 7.2 Required Components of Controlled Substance Prescriptions 7.3 Electronic Prescriptions for Controlled Substances (EPCS) & Security Requirements 7.4 Emergency Schedule II Prescriptions & Partial Filling Rules (CARA Act)
8 Chapter 8: Controlled Substance Ordering, Inventory & Recordkeeping
8.1 Ordering Schedule II Substances: CSOS & DEA Form 222 Execution 8.2 Controlled Substance Inventory Requirements (Initial, Biennial, Count Exactness) 8.3 Theft, Significant Loss (DEA Form 106) & Disposal/Destruction (DEA Form 41) 8.4 Prescription Transfers & Prescription Drug Monitoring Programs (PDMPs)
9 Chapter 9: Federal Pure Food, Drug & Cosmetic Act (FD&C Act) & Drug Safety
9.1 Adulteration vs. Misbranding: Statutory Definitions & Legal Violations 9.2 Prescription Labeling Requirements, Expiration Dates & Side Effect Statements 9.3 Poison Prevention Packaging Act (PPPA) & Child-Resistant Container Exemptions 9.4 Drug Recalls (Class I, II, III) & Market Withdrawals 9.5 Drug Product Selection, Generic Substitution & DAW Codes 9.6 Returning & Reusing Dispensed Drugs: Restocking, Redispensing & Repository Programs
10 Chapter 10: Drug Supply Chain Security Act (DSCSA) & Commercial Distribution
10.1 DSCSA Track-and-Trace Requirements: Transaction Information & Statements 10.2 Suspect & Illegitimate Product Verification, Quarantine & Notification 10.3 Prescription Drug Marketing Act (PDMA): Samples, Reimportation & Wholesale Distribution
11 Chapter 11: Compounding Standards: USP <795>, <797> & <800>
11.1 Section 503A vs. 503B Compounding Facilities (DQSA Architecture) 11.2 Non-Sterile Compounding (USP <795>) & Beyond-Use Dating (BUD) 11.3 Sterile Compounding (USP <797>): Air Quality, Cleanrooms & BUD 11.4 Hazardous Drug Handling (USP <800>): Engineering Controls & Personal Protective Equipment
12 Chapter 12: Pharmacy Operational Security, Records & Telepharmacy
12.1 Physical Pharmacy Security, Alarm Systems & Keyholder Rules 12.2 Mandatory Pharmacy Records Retention & Audit Inspection Readiness 12.3 Central Fill, Automated Dispensing Systems (ADS) & Telepharmacy Operations 12.4 HIPAA Privacy Rule, Patient Records & Breach Notification Protocols
11.1 Section 503A vs. 503B Compounding Facilities (DQSA Architecture)
Key Takeaways Explain This Topic AI
The Drug Quality and Security Act (DQSA) of 2013 established Section 503A (traditional compounding) and Section 503B (outsourcing facilities) under the FD&C Act in response to the 2012 NECC fungal meningitis outbreak.
Section 503A pharmacies compound pursuant to patient-specific prescriptions, are regulated primarily by State Boards of Pharmacy, and are exempt from FDA cGMP requirements and NDA/ANDA approvals.
Section 503B outsourcing facilities may compound in bulk without patient-specific prescriptions, must register with the FDA, and are strictly subject to Current Good Manufacturing Practice (cGMP) under 21 CFR Part 211.
503A compounding pharmacies are limited to distributing no more than 5% of their total compounded prescriptions out-of-state unless their home state has entered into a Memorandum of Understanding (MOU) with the FDA.
Section 503B facilities must report all compounded products to the FDA semi-annually (June and December) and report serious adverse events to the FDA within 15 calendar days using Form FDA 3500A.
Last updated: July 2026
11.1 Section 503A vs. 503B Compounding Facilities (DQSA Architecture)
MPJE Core Concept: The Drug Quality and Security Act (DQSA) of 2013 fundamentally split pharmaceutical compounding into two distinct statutory categories under the Federal Food, Drug, and Cosmetic Act (FD&C Act): Section 503A for traditional patient-specific compounding pharmacies and Section 503B for federal outsourcing facilities operating batch compounding without patient-specific prescriptions.
Legislative Origin: The Drug Quality and Security Act (DQSA) of 2013
In October 2012, a catastrophic public health crisis emerged when contaminated methylprednisolone acetate injections prepared by the New England Compounding Center (NECC) led to a nationwide fungal meningitis outbreak. The tragic event resulted in over 800 infections and more than 100 patient deaths. Investigation revealed that NECC functioned as a large-scale drug manufacturer under the guise of a state-licensed compounding pharmacy, distributing thousands of unsterilized vials across state lines without individual patient prescriptions and without adhering to federal manufacturing standards.
In response, Congress enacted the Drug Quality and Security Act (DQSA) on November 27, 2013. Title I of the DQSA, known as the Compounding Quality Act , clarified the jurisdictional boundary between state-regulated pharmacy compounding and FDA-regulated drug manufacturing by creating two distinct legal tracks:
- Section 503A — Traditional Compounding Pharmacies
- Section 503B — Outsourcing Facilities
Understanding the statutory requirements, exemptions, and compliance limits of both sections is critical for the Multistate Pharmacy Jurisprudence Examination (MPJE).
Section 503A: Traditional Compounding Pharmacies
Section 503A of the FD&C Act governs traditional pharmacy compounding. A 503A facility operates primarily under the regulatory authority of its respective State Board of Pharmacy , working in tandem with standards published by the United States Pharmacopeia (USP).
Core Conditions for Section 503A Exemption
To maintain statutory exemption from federal manufacturing requirements, a 503A compounding pharmacy must strictly satisfy the following criteria:
Patient-Specific Prescription Requirement: Compounding must be performed by a licensed pharmacist (in a state-licensed pharmacy or federal facility) or a licensed physician, pursuant to the receipt of a valid, patient-specific prescription order prior to dispensing.
Limited Anticipatory Compounding: A 503A pharmacy is permitted to compound small quantities of a drug product before receiving a valid prescription, but only if the compounding is based on a documented history of receiving valid prescription orders generated by an established relationship between the pharmacist, the patient, and the prescriber.
USP Compliance: Compounded preparations must comply with applicable USP monographs and general chapters, specifically USP <795> (Non-Sterile Compounding), USP <797> (Sterile Compounding), and USP <800> (Hazardous Drug Handling).
Bulk Drug Substances Standards: Bulk active pharmaceutical ingredients (APIs) used in 503A compounding must:
- Comply with an official USP or National Formulary (NF) monograph, OR
- Be a component of an FDA-approved drug product, OR
Appear on the FDA's 503A Bulk Drug Substances List (Category 1 candidates).
Be accompanied by a valid Certificate of Analysis (CoA) and manufactured by an FDA-registered establishment.
Statutory Exemptions Granted to 503A Pharmacies
When a 503A pharmacy complies with all statutory conditions, its compounded preparations are explicitly exempt from three major sections of the FD&C Act:
Current Good Manufacturing Practice (cGMP) requirements under FD&C Act Section 501(a)(2)(B).
FDA New Drug Application (NDA) / Abbreviated New Drug Application (ANDA) pre-market approval requirements under FD&C Act Section 505.
Federal Adequate Directions for Use labeling requirements under FD&C Act Section 502(f)(1).
Key Restrictions on Section 503A Pharmacies
5% Out-of-State Distribution Limit: A 503A pharmacy cannot distribute compounded drug products out-of-state in an amount exceeding 5% of the total prescription orders dispensed or distributed by the pharmacy, UNLESS the pharmacy is located in a state that has entered into a formal Memorandum of Understanding (MOU) with the FDA regarding interstate compounding oversight.
Copies of Commercially Available Drugs: Section 503A strictly prohibits compounding drug products that are "essentially copies of a commercially available drug product." A product is considered essentially a copy unless there is a change made for an individual patient that produces a significant difference for that patient as identified by the prescribing practitioner (e.g., removing a specific dye or allergen, or formulating an oral liquid for a pediatric patient unable to swallow commercial tablets).
Prohibited Compounds: Pharmacies cannot compound drug products that have been withdrawn or removed from the market by the FDA for reasons of safety or effectiveness.
Section 503B: Outsourcing Facilities
Section 503B created a new voluntary statutory class of compounding entities known as Outsourcing Facilities . Section 503B was specifically designed to accommodate hospitals, clinics, and health systems requiring bulk, non-patient-specific compounded sterile preparations for office use.
Core Characteristics of Section 503B Facilities
Elective Registration: An entity qualifies as a 503B facility by electing to register as an "Outsourcing Facility" with the FDA. Once registered, it is subject to direct FDA inspection and federal regulatory oversight.
No Patient-Specific Prescription Required: Section 503B facilities are permitted to compound and distribute sterile (and non-sterile) drugs in bulk for "office use" without obtaining individual patient-specific prescriptions prior to compounding or shipping.
Pharmacist Supervision: Compounding must occur under the direct oversight of a licensed pharmacist at a registered geographic location.
Federal Compliance & cGMP Requirements
Unlike 503A pharmacies, Section 503B outsourcing facilities are NOT exempt from federal Current Good Manufacturing Practice (cGMP) regulations under 21 CFR Part 211. They must implement rigorous industrial manufacturing standards, including:
Validated sterilization processes and environmental monitoring controls.
Extensive batch stability testing and container-closure integrity validation.
Comprehensive quality control unit oversight for raw materials, finished products, and release testing.
Statutory Exemptions Granted to 503B Facilities
Section 503B facilities receive exemptions from:
FDA NDA/ANDA approval requirements under Section 505.
Federal Adequate Directions for Use labeling requirements under Section 502(f)(1) (provided 503B federal labeling rules are met).
However, 503B facilities are NOT exempt from cGMP or FDA risk-based inspection schedules.
Mandatory Federal Reporting Obligations
Semi-Annual Drug Production Reporting: Every registered 503B facility must report to the FDA twice per year—during the months of June and December . The report must list all drug products compounded during the preceding 6-month period, specifying:
The active pharmaceutical ingredient (API) name, source, and National Drug Code (NDC) of the source bulk drug.
Strength, dosage form, and package size.
Total number of units produced and distributed.
Adverse Event Reporting: Section 503B facilities must submit all serious adverse drug experiences to the FDA within 15 calendar days of receiving notice, utilizing Form FDA 3500A (or electronic equivalent).
FDA Inspection Schedule: 503B facilities are subject to risk-based federal FDA inspections upon registration and routinely thereafter. Facilities must pay an annual federal registration fee and re-inspection fees.
Required Labeling for 503B Compounded Products
The container label of every 503B compounded preparation must prominently display:
The statement "This is a compounded drug."
The name, address, and phone number of the Section 503B outsourcing facility.
The facility lot/batch number, date compounded, and assigned expiration date/BUD.
Storage instructions and list of active and inactive ingredients.
The statement "Not for resale" and "Office use only" (unless dispensed pursuant to a patient-specific prescription).
Section 503A vs. Section 503B Statutory Comparison
- Regulatory Dimension Section 503A Traditional Pharmacy Section 503B Outsourcing Facility
- Primary Regulatory Authority State Board of Pharmacy Food and Drug Administration (FDA)
- Patient-Specific Prescription Required (or limited anticipatory) Not Required (permits bulk office use)
- cGMP Compliance (21 CFR 211) Exempt (Must follow USP standards) Mandatory (Strict cGMP compliance)
- FDA Pre-Market Approval (NDA/ANDA) Exempt Exempt
- Out-of-State Distribution Capped at 5% unless State has FDA MOU Unlimited interstate distribution permitted
- FDA Production Reporting None required Mandatory semi-annually (June & Dec)
- Adverse Event Reporting State Board rules apply Mandatory to FDA within 15 calendar days
Bulk API Source Requirements USP/NF monograph, approved drug, or 503A list 503B Bulk List or FDA Drug Shortage list
Commercial Copy Restrictions Cannot compound copies without significant difference Cannot compound copies without active shortage status